Life Technologies & IMEGEN Develop Fast and Accurate Full Solution Horse DNA Test for Meat Products

 Life Technologies & IMEGEN Develop Fast and Accurate Full Solution Horse DNA
                            Test for Meat Products

  PR Newswire

  GLASGOW, United Kingdom, March 1, 2013

- RapidFinder™ Equine ID Kit detects the presence of equine DNA extracted from
                  meat samples to help allay public concern

GLASGOW, United Kingdom, March 1, 2013 /PRNewswire/ -- Life Technologies
Corporation (NASDAQ: LIFE) today announces that it's developed the
RapidFinder™ Equine ID Kit in conjunction with the Instituto de Medicina
Genomica (IMEGEN) that detects the presence of equine DNA extracted from meat
samples. The kit is optimized for its use in all Applied Biosystems Real-Time
PCR Instruments.

"As global leaders in food testing products we recognise the importance of
public confidence in knowing that the meat on their plate is safe to eat and
is exactly what it says on the label," said Nir Nimrodi, Life Technologies'
Vice President and General Manager Animal Health & Food Safety. "The
RapidFinder™ Equine ID Kit is fast and accurate and will identify the presence
of horse DNA from sample to result in the same day and will provide improved
traceability and control within the food supply chain."

Life Technologies offers a full solution that includes a horse DNA
quantification kit, which is recommended by the EU. The kit comprises:

  *RapidFinder™ Equine ID Kit provides all the reagents required for 48
    reactions. The detection limit is 0.01% (w/w) in fresh meat and includes a
    positive control consisting of 0.1% horse DNA.
  *RapidFinder™ Quant Equine Set has a quantification limit: 0.05% (w/w) and
    includes the standard for quantification.

The RapidFinder™ Equine ID Kit is available immediately in Europe, Middle East
& Africa and via Life Technologies distributors according to local regulatory
requirements.

Along with customized PCR assays and reagents, Life Technologies also provides
testing kits for other meat products such as pork, and the RapidFinder™ STEC
Detection Workflow is a complete, validated screening system for E. coli
O157:H7 and the six non-O157 STECs. This system has been awarded a U.S.
Department of Agriculture (USDA) "Letter of No Objection" and provides meat
producers with a simple, accurate, and fast solution for efficiently
responding to new screening regulations for these pathogens.

The discovery of horsemeat in processed beef products sold by a number of
European retailers last month resulted in a series of product recalls and
thrown the spotlight on the food industry's supply chain. It has also inspired
a stricter food-testing regime across Europe.

About Life Technologies Life Technologies Corporation (NASDAQ: LIFE) is a
global biotechnology company that is committed to providing the most
innovative products and services to leading customers in the fields of
scientific research, genetic analysis and applied sciences. With a presence in
more than 180 countries, the company's portfolio of 50,000 end-to-end
solutions are secured by more than 5,000 patents and licenses that span the
entire biological spectrum -- scientific exploration, molecular diagnostics,
21st century forensics, regenerative medicine and agricultural research. Life
Technologies has approximately 10,000 employees and had sales of $3.8 billion
in 2012.

Life Technologies' Safe Harbor Statement This press release includes
forward-looking statements about our anticipated results that involve risks
and uncertainties. Some of the information contained in this press release,
including, but not limited to, statements as to industry trends and Life
Technologies' plans, objectives, expectations and strategy for its business,
contains forward-looking statements that are subject to risks and
uncertainties that could cause actual results or events to differ materially
from those expressed or implied by such forward-looking statements. Any
statements that are not statements of historical fact are forward-looking
statements. When used, the words "believe," "plan," "intend," "anticipate,"
"target," "estimate," "expect" and the like, and/or future tense or
conditional constructions ("will," "may," "could," "should," etc.), or similar
expressions, identify certain of these forward-looking statements. Important
factors which could cause actual results to differ materially from those in
the forward-looking statements are detailed in filings made by Life
Technologies with the Securities and Exchange Commission. Life Technologies
undertakes no obligation to update or revise any such forward-looking
statements to reflect subsequent events or circumstances.

About Instituto de Medicina Genomica (IMEGEN) IMEGEN is a privately owned
biotechnology company founded in 2009 that applies genomics to the development
of food security tests and genetic tests for human rare diseases. In the area
of food security, a wide portfolio of tests and kits are available for the
control of GMO materials and animal species identification in food and
feedstuff. In the biomedical area, more than 1,500 in-house genetic tests are
available for the identification of mutations causing rare diseases of genetic
origin. IMEGEN employs 24 people and operates in more than 20 countries in
Europe and America. IMEGEN had sales of $2.6 million in 2012. Visit us at our
website: www.imegen.es/english

(Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO )

Media Contacts: David RobertsonCorporate Communications Europe, Middle East &
AfricaLife Technologies Email: david.robertson@lifetech.com Tel:
+44-141-814-5889

Website: http://www.lifetechnologies.com
Website: http://www.imegen.es/english
 
Press spacebar to pause and continue. Press esc to stop.